Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year 2021 Concepts
- Asthma and Allergic Diseases Cooperative Research Centers
- Childhood Asthma in Urban Settings Clinical Research Network
- Development of Radiation/Nuclear Medical Countermeasures (MCMs)
- Molecular Mechanisms of Combination Adjuvants
- NHP MHC Allele Discovery and Typing Technology Development
- Clinical Data and Safety Management Center
Asthma and Allergic Diseases Cooperative Research Centers
For the published request for applications, see the March 23, 2020 Guide announcement, Asthma and Allergic Diseases Cooperative Research Centers (U19, Clinical Trial Optional).
Childhood Asthma in Urban Settings Clinical Research Network
For the published requests for applications, see the January 29, 2020 Guide announcements:
- Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center (UM1 Clinical Trial Required)
- Childhood Asthma in Urban Settings - Clinical Research Centers (U01 Clinical Trial Optional)
Development of Radiation/Nuclear Medical Countermeasures (MCMs)
Broad Agency Announcement—proposed FY 2021 initiative
Contact: Albert Nguyen
Objective: This initiative will address gaps and accelerate the research and development of MCMs to mitigate/treat acute and/or delayed radiation syndromes (DEARE).
Description: The NIAID Radiation and Nuclear Countermeasures Program has been charged with addressing radiation-induced injuries resulting from a radiological/nuclear incident and to develop MCMs to mitigate or treat these radiation-induced injuries. The goal of this broad agency announcement (BAA) is to support developing safe and effective MCMs, thereby leading to a reduction in radiation-associated morbidities and mortalities. Contracts awarded under this BAA will support efficacy studies, animal safety, manufacturing, and other investigational new drug-enabling activities.
Molecular Mechanisms of Combination Adjuvants
Request for Applications—proposed FY 2021 initiative
Contact: Cheryl Lapham
Objective: The use of adjuvants in vaccines can enhance vaccine efficacy, promote dose sparing, and may contribute to more rapid and durable immune protection against pathogens. Although a single adjuvant can enhance immune responses and the efficacy of a vaccine, it is not always sufficient for long-term protection, particularly in vulnerable populations. Adjuvant combinations that target multiple receptors and pathways hold great potential to improve protective vaccine responses. The primary objective of the Molecular Mechanisms of Combination Adjuvants program is to support studies of adjuvant combinations that define the molecular and immunological mechanisms by which these combinations work. The work will ultimately facilitate developing optimized, pathogen-specific combinations that improve the duration, quality, and magnitude of vaccine-induced immune responses.
Description: This funding opportunity announcement solicits applications on the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are used in these studies must already have shown immune-boosting activity when used individually in licensed or unlicensed vaccines (e.g., experimental or candidate vaccines).
Applications should include
- Analysis of induction of innate or adaptive immune memory
- At least one non-Toll-like receptor ligand (change from previous cycle)
- Qualitative as well as quantitative measures of effectiveness, such as avidity of T-cell receptors and B-cell receptors, breadth of immune responses, or identification of immune correlates and epitope specificity
- Logical rationale for specific combinations
- A model antigen for testing efficacy
- Some measures of safety
NHP MHC Allele Discovery and Typing Technology Development
For the published broad agency announcement, see the November 25, 2019 solicitation, NHP MHC and KIR Allele Discovery and Typing Technology Development.
Clinical Data and Safety Management Center
For the published request for proposals, see the June 16, 2020 solicitation, NIAID Clinical Data and Safety Management Center (CDSMC).